Activity of ixabepilone and PARP inhibitors in triple-negative breast cancer (TNBC) based on gene expression.

被引：0
|
作者：
Horak, C. E.
Alexe, G.
Baselga, J.
Vahdat, L. T.
Valero, V.
Xing, G.
Mukhopadhyay, P.
Opatt, D. M.
Sparano, J.
机构：
[1] Bristol Myers Squibb, Hopewell, NY USA
[2] Bristol Myers Squibb, Pennington, NJ USA
[3] Vall dHebron Univ Hosp, Barcelona, Spain
[4] Weill Cornell Med Coll, New York, NY USA
[5] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[6] Bristol Myers Squibb Co, Wallingford, CT 06492 USA
[7] Bristol Myers Squibb, Plainsboro, NJ USA
[8] Yeshiva Univ Albert Einstein Coll Med, Jack D Weiler Hosp, Bronx, NY 10461 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 28卷 / 15期
关键词：
D O I：
10.1200/jco.2010.28.15_suppl.601
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
601
引用
收藏
页数：1
相关论文
共 50 条
  • [1] PARP Inhibitors in the Treatment of Triple-Negative Breast Cancer
    Jill J. J. Geenen
    Sabine C. Linn
    Jos H. Beijnen
    Jan H. M. Schellens
    Clinical Pharmacokinetics, 2018, 57 : 427 - 437
  • [2] PARP Inhibitors in the Treatment of Triple-Negative Breast Cancer
    Geenen, Jill J. J.
    Linn, Sabine C.
    Beijnen, Jos H.
    Schellens, Jan H. M.
    CLINICAL PHARMACOKINETICS, 2018, 57 (04) : 427 - 437
  • [3] Judy Garber on PARP inhibitors for triple-negative breast cancer
    Garber, Judy
    ONCOLOGY-NEW YORK, 2017, 31 (11): : 814 - +
  • [4] BRCA gene activity in triple-negative breast cancer (TNBC). Relevance for prognosis and therapy?
    Hüttemann U.
    Langer E.
    Schönherr A.
    Zwiefel K.
    Neumann M.
    Janni W.
    Mohrmann S.
    Der Gynäkologe, 2010, 43 (12): : 1002 - 1007
  • [5] Triple-negative breast cancer (TNBC) phosphoproteomics
    Gaitero, Sara Fernandez
    Zagorac, Ivana
    Lopez-Acosta, Jose Francisco
    Gomez-Lopez, Gonzalo
    Pisano, David Gonzalez
    Peralta, Javier Munoz
    Manso, Luis
    Alonso, Soledad
    Penning, Renske
    Altelaar, Maarten
    Heck, Albert J. R.
    Quintela-Fandino, Miguel
    CANCER RESEARCH, 2017, 77
  • [6] New Perspectives for Resistance to PARP Inhibitors in Triple-Negative Breast Cancer
    Han, Ye
    Yu, Xiaopeng
    Li, Shuqiang
    Tian, Ye
    Liu, Caigang
    FRONTIERS IN ONCOLOGY, 2020, 10
  • [7] Race-specific gene expression patterns in triple-negative breast cancer (TNBC) cases
    Martini, Rachel
    White, Jason
    Verma, Akanksha
    Elemento, Olivier
    Newman, Lisa
    Upender, Manne
    Yates, Clayton
    Davis, Melissa
    CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2020, 29 (06)
  • [8] Combination benefit between PARP inhibitor niraparib and angiogenesis inhibitors in PDX models of triple-negative breast cancer (TNBC).
    Zhou, Yinghui
    Wang, Sarah
    Mikule, Keith
    Ramaswamy, Sridhar
    Hanke, Jeffrey
    Wang, Jing Yu
    MOLECULAR CANCER RESEARCH, 2018, 16 (08) : 32 - 33
  • [9] The Role of Immunotherapy in Triple-Negative Breast Cancer (TNBC)
    Michaels, Elena
    Chen, Nan
    Nanda, Rita
    CLINICAL BREAST CANCER, 2024, 24 (04) : 263 - 270
  • [10] Neoadjuvant treatments for triple-negative breast cancer (TNBC)
    von Minckwitz, G.
    Martin, M.
    ANNALS OF ONCOLOGY, 2012, 23 : 35 - 39
12345